Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News 60 Degrees Pharmaceuticals Inc SXTPW


Primary Symbol: SXTP

Healthcare Biotechnology
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19... see more

Recent & Breaking News (NDAQ:SXTP)

60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website

GlobeNewswire April 15, 2026

60 Degrees Pharmaceuticals Announces 2025 Annual Results

GlobeNewswire March 31, 2026

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

GlobeNewswire March 18, 2026

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

GlobeNewswire March 11, 2026

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

GlobeNewswire February 2, 2026

60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use

GlobeNewswire January 28, 2026

60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention

GlobeNewswire January 22, 2026

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

GlobeNewswire January 15, 2026

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

GlobeNewswire December 29, 2025

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

GlobeNewswire December 11, 2025

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

GlobeNewswire November 21, 2025

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

GlobeNewswire November 13, 2025

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

GlobeNewswire October 15, 2025

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

GlobeNewswire October 9, 2025

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 3, 2025

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire August 21, 2025

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

GlobeNewswire August 19, 2025

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

GlobeNewswire August 13, 2025

60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

GlobeNewswire July 17, 2025

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

GlobeNewswire July 16, 2025

Podcasts